Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.05
SYNH's Cash-to-Debt is ranked lower than
92% of the 261 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.52 vs. SYNH: 0.05 )
Ranked among companies with meaningful Cash-to-Debt only.
SYNH' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05  Med: 0.2 Max: 0.37
Current: 0.05
0.05
0.37
Equity-to-Asset 0.39
SYNH's Equity-to-Asset is ranked lower than
77% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. SYNH: 0.39 )
Ranked among companies with meaningful Equity-to-Asset only.
SYNH' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.18  Med: 0.24 Max: 0.42
Current: 0.39
0.18
0.42
Debt-to-Equity 1.02
SYNH's Debt-to-Equity is ranked lower than
80% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.36 vs. SYNH: 1.02 )
Ranked among companies with meaningful Debt-to-Equity only.
SYNH' s Debt-to-Equity Range Over the Past 10 Years
Min: 1  Med: 1.57 Max: 2.31
Current: 1.02
1
2.31
Debt-to-EBITDA 7.31
SYNH's Debt-to-EBITDA is ranked lower than
98% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.77 vs. SYNH: 7.31 )
Ranked among companies with meaningful Debt-to-EBITDA only.
SYNH' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.42  Med: 5.98 Max: 22.82
Current: 7.31
2.42
22.82
Interest Coverage 2.08
SYNH's Interest Coverage is ranked lower than
99.99% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.01 vs. SYNH: 2.08 )
Ranked among companies with meaningful Interest Coverage only.
SYNH' s Interest Coverage Range Over the Past 10 Years
Min: 0.03  Med: 2.14 Max: 14.32
Current: 2.08
0.03
14.32
Piotroski F-Score: 4
Altman Z-Score: 1.21
Beneish M-Score: -1.94
WACC vs ROIC
8.27%
7.22%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 5.45
SYNH's Operating Margin % is ranked lower than
51% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.59 vs. SYNH: 5.45 )
Ranked among companies with meaningful Operating Margin % only.
SYNH' s Operating Margin % Range Over the Past 10 Years
Min: -0.31  Med: 5.92 Max: 11.41
Current: 5.45
-0.31
11.41
Net Margin % -0.84
SYNH's Net Margin % is ranked lower than
51% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.48 vs. SYNH: -0.84 )
Ranked among companies with meaningful Net Margin % only.
SYNH' s Net Margin % Range Over the Past 10 Years
Min: -9.08  Med: -4.17 Max: 8.37
Current: -0.84
-9.08
8.37
ROE % -1.25
SYNH's ROE % is ranked lower than
53% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.75 vs. SYNH: -1.25 )
Ranked among companies with meaningful ROE % only.
SYNH' s ROE % Range Over the Past 10 Years
Min: -37.63  Med: -8.24 Max: 43.41
Current: -1.25
-37.63
43.41
ROA % -0.50
SYNH's ROA % is ranked higher than
51% of the 262 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.54 vs. SYNH: -0.50 )
Ranked among companies with meaningful ROA % only.
SYNH' s ROA % Range Over the Past 10 Years
Min: -9.4  Med: -2.57 Max: 9.54
Current: -0.5
-9.4
9.54
ROC (Joel Greenblatt) % 61.64
SYNH's ROC (Joel Greenblatt) % is ranked lower than
56% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -9.57 vs. SYNH: 61.64 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SYNH' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -154.57  Med: 65.55 Max: 331.19
Current: 61.64
-154.57
331.19
3-Year Revenue Growth Rate 17.30
SYNH's 3-Year Revenue Growth Rate is ranked higher than
79% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. SYNH: 17.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
SYNH' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 11.8  Med: 16.05 Max: 20.7
Current: 17.3
11.8
20.7
3-Year EBITDA Growth Rate 5.70
SYNH's 3-Year EBITDA Growth Rate is ranked lower than
57% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. SYNH: 5.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
SYNH' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 5.7  Med: 29.55 Max: 56.1
Current: 5.7
5.7
56.1
3-Year EPS without NRI Growth Rate -53.70
SYNH's 3-Year EPS without NRI Growth Rate is ranked lower than
91% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. SYNH: -53.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
SYNH' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: -53.7
Current: -53.7
GuruFocus has detected 1 Warning Sign with Syneos Health Inc SYNH.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SYNH's 30-Y Financials

Financials (Next Earnings Date: 2019-05-09)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2018

SYNH Guru Trades in Q1 2018

Ron Baron 400,000 sh (New)
Pioneer Investments 7,627 sh (New)
Andreas Halvorsen 1,925,548 sh (+23.55%)
Steven Cohen 497,600 sh (+106.13%)
Jana Partners Sold Out
» More
Q2 2018

SYNH Guru Trades in Q2 2018

Vanguard Health Care Fund 475,600 sh (New)
Steven Cohen 530,800 sh (+6.67%)
Ron Baron Sold Out
Andreas Halvorsen 1,772,781 sh (-7.93%)
Pioneer Investments 5,600 sh (-26.58%)
» More
Q3 2018

SYNH Guru Trades in Q3 2018

Joel Greenblatt 11,360 sh (New)
Paul Tudor Jones 9,506 sh (New)
Andreas Halvorsen 1,804,104 sh (+1.77%)
Pioneer Investments 104,451 sh (+1765.20%)
Vanguard Health Care Fund 475,600 sh (unchged)
Steven Cohen 318,800 sh (-39.94%)
» More
Q4 2018

SYNH Guru Trades in Q4 2018

Pioneer Investments 249,327 sh (+138.70%)
Joel Greenblatt 48,619 sh (+327.98%)
Vanguard Health Care Fund 475,600 sh (unchged)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Andreas Halvorsen 1,756,350 sh (-2.65%)
» More
» Details

Insider Trades

Latest Guru Trades with SYNH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 541714    SIC: 8731
Compare:NAS:NEOG, SHSE:603658, NAS:BRKR, NAS:FMI, MIL:DIA, BSP:DASA3, BSP:FLRY3, NYSE:CRL, NAS:EXAS, NAS:PRAH, XTER:AFX, TSE:4544, SHSE:603882, SZSE:300463, NAS:MYGN, SZSE:300244, NAS:QDEL, SZSE:300482, NAS:DXCM, NAS:ABAX » details
Traded in other countries:8IN.Germany,
Headquarter Location:USA
Syneos Health Inc is a Contract Research Organization providing clinical development services for biopharmaceutical & medical device industries. It operates in North America, Europe, Middle East and Africa, Asia-Pacific and Latin America.

Syneos is a global contract research and commercialization organization that provides services to pharmaceutical and biotechnology companies. Its clinical solutions segment offers early- to late-stage clinical trial support that ranges from specialized staffing models to strategic partnerships that oversee nearly all aspects of a drug program, while the company's commercialization solutions includes outsourced sales, consulting, public relations, and advertising services.

Top Ranked Articles about Syneos Health Inc

Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for Syneos Health, Inc. Investors
RM LAW Announces Class Action Lawsuit Against Syneos Health, Inc.
SYNEOS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Syneos Health, Inc. – SYNH
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Syneos Health, Inc. To Contact The Firm
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syneos Health, Inc. - SYNH
Syneos Health Schedules Fourth Quarter and Year End 2018 Earnings Call for Monday, March 18, 2019
SYNH APRIL 30th DEADLINE REMINDER: Rosen Law Firm Reminds Syneos Health, Inc. Investors of Important Deadline in Securities Class Action Lawsuit; Encourages Investors With Losses in Excess of $100K to Contact the Firm – SYNH
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Against SYNEOS HEALTH, INC. – SYNH
SYNH DEADLINE ALERT: Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against Syneos Health, Inc. – SYNH
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Syneos Health, Inc. To Contact The Firm

Ratios

vs
industry
vs
history
PE Ratio 223.48
SYNH's PE Ratio is ranked lower than
99.99% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.00 vs. SYNH: 223.48 )
Ranked among companies with meaningful PE Ratio only.
SYNH' s PE Ratio Range Over the Past 10 Years
Min: 18.52  Med: 26.24 Max: 2501.5
Current: 223.48
18.52
2501.5
Forward PE Ratio 15.46
SYNH's Forward PE Ratio is ranked higher than
92% of the 40 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. SYNH: 15.46 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 223.48
SYNH's PE Ratio without NRI is ranked lower than
99.99% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.56 vs. SYNH: 223.48 )
Ranked among companies with meaningful PE Ratio without NRI only.
SYNH' s PE Ratio without NRI Range Over the Past 10 Years
Min: 18.52  Med: 26.24 Max: 2501.5
Current: 223.48
18.52
2501.5
Price-to-Owner-Earnings 21.35
SYNH's Price-to-Owner-Earnings is ranked lower than
82% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.75 vs. SYNH: 21.35 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
SYNH' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 20.62  Med: 56.73 Max: 103.75
Current: 21.35
20.62
103.75
PB Ratio 1.95
SYNH's PB Ratio is ranked higher than
88% of the 245 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.02 vs. SYNH: 1.95 )
Ranked among companies with meaningful PB Ratio only.
SYNH' s PB Ratio Range Over the Past 10 Years
Min: 1.2  Med: 7.09 Max: 12.19
Current: 1.95
1.2
12.19
PS Ratio 1.23
SYNH's PS Ratio is ranked higher than
84% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.81 vs. SYNH: 1.23 )
Ranked among companies with meaningful PS Ratio only.
SYNH' s PS Ratio Range Over the Past 10 Years
Min: 0.91  Med: 1.56 Max: 2.29
Current: 1.23
0.91
2.29
Price-to-Free-Cash-Flow 21.72
SYNH's Price-to-Free-Cash-Flow is ranked higher than
69% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.22 vs. SYNH: 21.72 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
SYNH' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 11.26  Med: 19.83 Max: 125.14
Current: 21.72
11.26
125.14
Price-to-Operating-Cash-Flow 17.81
SYNH's Price-to-Operating-Cash-Flow is ranked higher than
69% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.94 vs. SYNH: 17.81 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
SYNH' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.11  Med: 16.64 Max: 46.11
Current: 17.81
9.11
46.11
EV-to-EBIT 42.57
SYNH's EV-to-EBIT is ranked lower than
99.99% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.06 vs. SYNH: 42.57 )
Ranked among companies with meaningful EV-to-EBIT only.
SYNH' s EV-to-EBIT Range Over the Past 10 Years
Min: -574.5  Med: 22 Max: 81
Current: 42.57
-574.5
81
EV-to-EBITDA 17.33
SYNH's EV-to-EBITDA is ranked lower than
92% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.75 vs. SYNH: 17.33 )
Ranked among companies with meaningful EV-to-EBITDA only.
SYNH' s EV-to-EBITDA Range Over the Past 10 Years
Min: 12.2  Med: 19.8 Max: 80.3
Current: 17.33
12.2
80.3
EV-to-Revenue 1.82
SYNH's EV-to-Revenue is ranked higher than
68% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.24 vs. SYNH: 1.82 )
Ranked among companies with meaningful EV-to-Revenue only.
SYNH' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.4  Med: 2 Max: 3.9
Current: 1.82
1.4
3.9
PEG Ratio 13.55
SYNH's PEG Ratio is ranked lower than
99.99% of the 48 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.26 vs. SYNH: 13.55 )
Ranked among companies with meaningful PEG Ratio only.
SYNH' s PEG Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: 13.55
Current Ratio 0.99
SYNH's Current Ratio is ranked lower than
84% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.58 vs. SYNH: 0.99 )
Ranked among companies with meaningful Current Ratio only.
SYNH' s Current Ratio Range Over the Past 10 Years
Min: 0.89  Med: 1.12 Max: 1.23
Current: 0.99
0.89
1.23
Quick Ratio 0.99
SYNH's Quick Ratio is ranked lower than
73% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. SYNH: 0.99 )
Ranked among companies with meaningful Quick Ratio only.
SYNH' s Quick Ratio Range Over the Past 10 Years
Min: 0.89  Med: 1.12 Max: 1.23
Current: 0.99
0.89
1.23
Days Sales Outstanding 60.57
SYNH's Days Sales Outstanding is ranked lower than
69% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.51 vs. SYNH: 60.57 )
Ranked among companies with meaningful Days Sales Outstanding only.
SYNH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.34  Med: 47.55 Max: 87.83
Current: 60.57
40.34
87.83
Days Payable 10.48
SYNH's Days Payable is ranked lower than
94% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. SYNH: 10.48 )
Ranked among companies with meaningful Days Payable only.
SYNH' s Days Payable Range Over the Past 10 Years
Min: 4.52  Med: 8 Max: 10.48
Current: 10.48
4.52
10.48

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -24.80
SYNH's 3-Year Average Share Buyback Ratio is ranked higher than
54% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.90 vs. SYNH: -24.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SYNH' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -24.8  Med: -5.5 Max: -1
Current: -24.8
-24.8
-1

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) % 2.35
SYNH's Earnings Yield (Greenblatt) % is ranked higher than
52% of the 265 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.98 vs. SYNH: 2.35 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SYNH' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1.3  Med: 2.4 Max: 5.9
Current: 2.35
-1.3
5.9
Forward Rate of Return (Yacktman) % 18.42
SYNH's Forward Rate of Return (Yacktman) % is ranked lower than
99.99% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.45 vs. SYNH: 18.42 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
SYNH' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: 18.42

More Statistics

Revenue (TTM) (Mil) $4,390.12
EPS (TTM) $ 0.23
Beta1.21
Volatility53.80%
52-Week Range $34.40 - 56.34
Shares Outstanding (Mil)103.70

Analyst Estimate

Dec19 Dec20
Revenue (Mil $) 4,660 4,950
EBIT (Mil $) 482 617
EBITDA (Mil $) 617 692
EPS ($) 1.90 2.74
EPS without NRI ($) 1.90 2.74
EPS Growth Rate
(Future 3Y To 5Y Estimate)
8.10%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}